Search | Clinical Trials Finder

Conditions: Obstetric Labor, Premature
Interventions: Indomethacin, Nifedipine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pregnancy Toxemia, Hypertension, Proteinuria
Interventions: methyldopa, labetalol, nifedipine, clonidine; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension in Pregnancy
Interventions: Nifedipine Extended-Release Tablets; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension
Interventions: Hydrochlorothiazide, Lisinopril, Lisinopril and Hydrochlorothiazide, Nifedipine XL, Metoprolol tartrate, Atenolol, Valsartan, Doxazosin, Clonidine, Hydralazine, Metoprolol succinate, Amlodipine; Drug
Lead sponsor: Creighton University; Other
Eligibility: 25 Years to 80 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hypertension in Pregnancy, Obstetrical Complications
Interventions: Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg, Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHg; Drug · Other
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: 14 Years to 56 Years · Female only
Enrollment: 4,120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Nifedipine; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 14 Years to 35 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions: Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine; Drug
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 20
States / cities: La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more

Conditions: Hypertension in Pregnancy, Preeclampsia
Interventions: Nifedipine, Labetalol; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Preeclampsia Severe
Interventions: Nifedipine 30 MG, Placebos; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Erectile Dysfunction
Interventions: Vardenafil ODT, (Staxyn, BAY38-9456), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 65 Years to 80 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Miami, Florida • Knoxville, Tennessee

Conditions: Systolic Hypertension, Pregnancy Related, Diastolic Hypertension, Cardiac Output, Low, Cardiac Output, High
Interventions: Labetalol, Atenolol, Nifedipine; Drug
Lead sponsor: Marshall University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Huntington, West Virginia

Conditions: Postpartum Complication, Maternal Hypertension, High Blood Pressure
Interventions: Oral Nifedipine, Oral Labetalol; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Hypertension, Pregnancy-Induced
Interventions: Nifedipine ER; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Chicago, Illinois • Milwaukee, Wisconsin

Conditions: Obesity, Morbid, Preeclampsia
Interventions: Labetalol Hydrochloride 200 mg, NIFEdipine 60 mg, Atenolol 25 mg; Drug
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Chronic Hypertension Complicating Pregnancy (Diagnosis), Preeclampsia
Interventions: Labetalol Hydrocholoride 200 mg orally every 12 hours, Nifedipine 60 mg orally daily, Atenolol 25 mg daily; Drug
Lead sponsor: University of Tennessee Medical Center; Other
Eligibility: 18 Years to 51 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Hypertension, Postpartum Preeclampsia
Interventions: Nifedipine and Enalapril, Nifedipine and Labetalol; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Preterm Labor
Interventions: 1 Magnesium Sulfate, Nifedipine, Indomethacin; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Hypertension, COVID
Interventions: ACEI/ARB, Non-ACEI/ARB, ACEI, ARB; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 22,213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hypertension
Interventions: Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress; Drug · Dietary Supplement · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Continuous Positive Airway Pressure, High Altitude Pulmonary Edema
Interventions: CPAP mask system, Nifedipine 30 MG, CPAP mask system without PEEP; Device · Drug
Lead sponsor: CommonSpirit Health; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Breckenridge, Colorado

Conditions: Hypertension
Interventions: Anti-hypertensive therapy, No anti-hypertensive therapy (unless BP is severe); Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 12 Years and older · Female only
Enrollment: 2,408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more

Conditions: Healthy
Interventions: Nifedipine Extended Release tablets 60 mg, single dose, ADALAT® CC Extended Release Tablets 60 mg; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Thalassemia, Iron Overload, Hemochromatosis
Interventions: Nifedipine, Phlebotomy, Urinalysis, Echocardiogram, Electrocardiogram; Drug · Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Postpartum Hypertension (PPHT)
Interventions: Labetalol, Nifedipine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Indomethacin Versus Nifedipine for Preterm Labor Tocolysis

Treatment Targets for Chronic Hypertension in Pregnancy

Persistent Postpartum Hypertension Pilot Trial

Black Education and Treatment of Hypertension (BEAT HTN)

Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Response to Anti-hypertensives in Pregnant and Postpartum Patients

Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor

Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

Safest Choice of Antihypertensive Regimen for Postpartum Hypertension

Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia

Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients

Impedance Cardiography to Decrease the Risk of Preeclampsia

Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study

Tocolysis for Preterm Labor

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

Treatment of Supine Hypertension in Autonomic Failure

Evaluating the Utility of Continuous Positive Airway Pressure in the Treatment of High Altitude Pulmonary Edema

Chronic Hypertension and Pregnancy (CHAP) Project

A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions

Oral Nifedipine to Treat Iron Overload

PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy